

Development of dual-functional hit/lead compounds targeting N3, a regulator of KRAS stability for the treatment of pancreatic cancer

Korea Research Institute of Bioscience and Biotechnology(KRIBB)

ONCOLOGY	Hit
Product Type	Small molecule (PROTAC)
Indication	Pancreatic cancer
Target	Stability of oncogenic KRAS protein
MoA(Mechanism of Action)	Targeting oncogenic N3 involved in the stabilization of KRAS protein
Competitiveness	Development of dual-functional PROTAC that simultaneously inhibits the expression of oncogenic proteins, N3 and KRAS
Development Stage	Hit
Route of Administration	Ministry of Health and Welfare